Harrow Health, Inc. (HROW) |
|
17.62 -0.41 (-2.27%)
|
03-22 12:05 |
|
Open: |
17.94 |
Pre. Close: |
18.03 |
|
High:
|
18.11 |
Low:
|
17.595 |
|
Volume:
|
79,979 |
Market Cap:
|
558(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:47:04 AM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 22.35 One year: 26.11 |
| Support: |
Support1: 16.71 Support2: 15.22 |
| Resistance: |
Resistance1: 19.13 Resistance2: 22.35 |
| Pivot: |
18.14  |
| Moving Average: |
MA(5): 17.76 MA(20): 17.97
MA(100): 14.54 MA(250): 10.59 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 57.9 %D(3): 51.4 |
| RSI: |
RSI(14): 49.6 |
| 52-week: |
High: 20.3 Low: 5.4 |
| Average Vol(K): |
3-Month: 341 (K) 10-Days: 425 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ HROW ] has closed above bottom band by 24.2%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
18.09 - 18.19 |
18.19 - 18.28 |
|
Low:
|
17.22 - 17.36 |
17.36 - 17.48 |
|
Close:
|
17.84 - 18.03 |
18.03 - 18.21 |
|
Company Description |
|
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California. |
Headline News |
Tue, 21 Mar 2023
Harrow Health Inc : A loss of 12 cents per share ... - Kalkine Media
Sun, 19 Mar 2023
ROSEN, A LEADING AND RANKED FIRM, Encourages Harrow ... - The Bakersfield Californian
Sat, 18 Mar 2023
HARROW HEALTH SHAREHOLDER ACTION REMINDER ... - PR Newswire
Fri, 17 Mar 2023
Harrow Health Shareholder Notice - Harrow Health (NASDAQ:HROW) - Benzinga
Fri, 17 Mar 2023
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Harrow Health ... - PR Newswire
Thu, 16 Mar 2023
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ... - Digital Journal
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
30 (M) |
| Shares Float |
22 (M) |
|
% Held by Insiders
|
7.7 (%) |
|
% Held by Institutions
|
62 (%) |
|
Shares Short
|
1,630 (K) |
|
Shares Short P.Month
|
1,130 (K) |
Stock Financials |
|
EPS
|
-0.76 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.05 |
|
Profit Margin (%)
|
-25.5 |
|
Operating Margin (%)
|
4.1 |
|
Return on Assets (ttm)
|
2.2 |
|
Return on Equity (ttm)
|
-264 |
|
Qtrly Rev. Growth
|
22 |
|
Gross Profit (p.s.)
|
1.82 |
|
Sales Per Share
|
2.96 |
|
EBITDA (p.s.)
|
0.2 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
4 (M) |
|
Levered Free Cash Flow
|
24 (M) |
Stock Valuations |
|
PE Ratio
|
-23.19 |
|
PEG Ratio
|
-1.9 |
|
Price to Book value
|
352.4 |
|
Price to Sales
|
5.93 |
|
Price to Cash Flow
|
133.56 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
